Estuary Biotherapeutics is focused on developing genetic medicines to treat autosomal dominant polycystic kidney disease (ADPKD) by addressing the underlying genetic causes of the disease through innovative gene therapy approaches
Estuary Biotherapeutics is focused on developing genetic medicines to treat autosomal dominant polycystic kidney disease (ADPKD) by addressing the underlying genetic causes of the disease through innovative gene therapy approaches.